Topics

Epizyme announces FDA filing acceptance of new drug application and priority review for tazemetostat to treat epithelioid sarcoma

06:03 EDT 26 Jul 2019 | Pharmaceutical Business Review

Epizyme has proposed an indication of metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery. The FDA granted Priority Review for the NDA and has set

The post Epizyme announces FDA filing acceptance of new drug application and priority review for tazemetostat to treat epithelioid sarcoma appeared first on Pharmaceutical Business review.

Original Article: Epizyme announces FDA filing acceptance of new drug application and priority review for tazemetostat to treat epithelioid sarcoma

NEXT ARTICLE

More From BioPortfolio on "Epizyme announces FDA filing acceptance of new drug application and priority review for tazemetostat to treat epithelioid sarcoma"

Quick Search

Relevant Topics

Surgical treatments
Surgery is a technology consisting of a physical intervention on tissues. All forms of surgery are considered invasive procedures; so-called "noninvasive surgery" usually refers to an excision that does not penetrate the structure being exci...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...